TLRY - Huge Benefits For Medical Marijuana Patients Opportunities For Innovation & Research – Industry Vets Weigh In On Germany's Cannabis Reform | Benzinga
The second most populated country in Europe, Germany, legalized recently marijuana. What does this mean?
Even though Germany's cannabis legalization is partial, it significantly impacts the country’s medical marijuana program by enabling personal possession, consumption and establishment of non-profit cannabis social clubs. To learn more about what this historic move means for the industry in Europe, Benzinga reached out to several industry experts.
We spoke with Dr. Constantin von der Groeben, a managing director of Demecan – the only German vertically integrated medicinal cannabis company; Denise Faltischek, a chief strategy officer and Head of International at Tilray Brands (NASDAQ:TLRY) (TSX:TLRY) and Jürgen Bickel, co-founder and managing director of Canopy Growth's (NASDAQ:CGC) Germany-based vaporization company Storz & Bickel.
Huge Benefits For Medical Marijuana Patients
Faltischek told Benzinga that "of particular importance to Tilray is the adoption of the new Medical Cannabis Act, MedCanG, which provides de-scheduling of cannabis as a narcotic, which we expect will significantly expand the medical cannabis market in Germany allowing for wider insurance coverage as well as enhanced accessibility to high-quality cannabis for medical patient."
Tilray Brand's medical division, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in over 20 countries and across five continents. It grew from being one of the first companies to become an approved licensed producer of medical ...